Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. (ParvOryx01)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Oryx GmbH & Co. KG
ClinicalTrials.gov Identifier:
NCT01301430
First received: February 21, 2011
Last updated: December 3, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2015
  Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)